Biotech By Damian Garde What if a pill could lower cholesterol like pricey injectables? Esperion intends to find out
Biotech By Kate Sheridan and Adam Feuerstein After repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia Therapeutics
Biotech By Adam Feuerstein With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
Biotech By Adam Feuerstein and Matthew Herper Gilead’s remdesivir sales are surging, but investors aren’t impressed
Biotech By Adam Feuerstein Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugs
Biotech By Adam Feuerstein Bluebird Bio intends to split into two companies, but for now, its troubles are also divided
Biotech By Matthew Herper Company dedicated to cutting drug prices raises lots of money, releases few details
Biotech By Adam Feuerstein Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome
Biotech By Anissa Gardizy — Boston Globe With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million
Biotech By Matthew Herper Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease
In the Lab By Sharon Begley CRISPR cures progeria in mice, raising hope for one-time therapy for a disease that causes rapid aging
Biotech By Kate Sheridan Siddhartha Mukherjee forms his second biotech company, focused on using cell therapy for solid tumors
Biotech By Adam Feuerstein The biotech scorecard for the first quarter: 17 stock-moving events to watch
Biotech By Adam Feuerstein and Damian Garde The biotech 2021 preview, from M&A to gene therapy and more
First Opinion By Shirley Leung ‘There are a lot of potential Modernas’: The ‘Massachusetts Miracle’ is alive and well
Biotech By Adam Feuerstein Uniqure’s hemophilia B gene therapy program on hold due to cancer diagnosis in treated patient
Biotech By Adam Feuerstein Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases
Adam's Take By Adam Feuerstein Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list